Literature DB >> 31168266

Expression of E cadherin and Ki 67: Emerging Prognostic Markers in Triple-Negative Breast Cancer.

Jayaprakash Shetty1, Chandrika Rao1.   

Abstract

Triple-negative breast cancer (TNBC) is an aggressive subgroup of breast cancer which lacks effective target therapy. Expression of biomarkers is one of the important deciding factors for treatment strategies. The aim of this study was to evaluate expression of E cadherin and Ki 67 in relation to clinicopathological features. This prospective observational study included 141 cases of TNBC. Immunohistochemical staining was employed to analyze two biomarkers: E cadherin and Ki 67 on formalin-fixed paraffin-embedded tumor samples obtained from patients defined as TNBC. The age of the patients ranged from 26 to 84 years. Positive lymph nodes were found in 82 (58.1%). The tumor was grade 3 in 105 (74.4%). The E cadherin receptor was positive in 83 (58.8%). The Ki Index was > 10% in 89 (63.12%). The Ki 67 expression was significantly associated with a high nuclear grade (p = 0.000). The significant association noted between loss of E cadherin expression and positive lymph node (p = 0.0296). According to the results, TNBCs are frequently associated with the younger age groups, and the majority is poorly differentiated. The majorities of these have high expression of the Ki 67 and significantly associated with the higher nuclear grade. Loss of E cadherin was significantly associated with positive lymph nodes. Hence, evaluating the expression of E cadherin and Ki 67 routinely would be helpful for evaluating prognostic implications.

Entities:  

Keywords:  E cadherin; Ki 67; Prognostic markers; Triple-negative breast cancer

Year:  2019        PMID: 31168266      PMCID: PMC6527631          DOI: 10.1007/s13193-019-00885-x

Source DB:  PubMed          Journal:  Indian J Surg Oncol        ISSN: 0975-7651


  9 in total

1.  The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancer.

Authors:  Dabei Tang; Shanqi Xu; Qingyuan Zhang; Wenhui Zhao
Journal:  Med Oncol       Date:  2011-04-26       Impact factor: 3.064

2.  Expression of p53, Ki-67, E-cadherin, N-cadherin and TOP2A in triple-negative breast cancer.

Authors:  Misako Nakagawa; Yoshimi Bando; Taeko Nagao; Masami Morimoto; Chikako Takai; Takamasa Ohnishi; Junko Honda; Takuya Moriya; Keisuke Izumi; Masako Takahashi; Mitsunori Sasa; Akira Tangoku
Journal:  Anticancer Res       Date:  2011-06       Impact factor: 2.480

3.  Cinical Significance of Androgen Receptor, CK-5/6, KI-67 and Molecular Subtypes in Breast Cancer.

Authors:  Münire Kayahan; Ufuk Oğuz İdiz; Zuhal Gucin; Fazilet Erözgen; Naim Memmi; Mahmut Müslümanoğlu
Journal:  J Breast Health       Date:  2014-10-01

Review 4.  Update on Immunohistochemical Analysis in Breast Lesions.

Authors:  Yan Peng; Yasmeen M Butt; Beiyun Chen; Xinmin Zhang; Ping Tang
Journal:  Arch Pathol Lab Med       Date:  2017-06-02       Impact factor: 5.534

5.  Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group.

Authors:  Mitch Dowsett; Torsten O Nielsen; Roger A'Hern; John Bartlett; R Charles Coombes; Jack Cuzick; Matthew Ellis; N Lynn Henry; Judith C Hugh; Tracy Lively; Lisa McShane; Soon Paik; Frederique Penault-Llorca; Ljudmila Prudkin; Meredith Regan; Janine Salter; Christos Sotiriou; Ian E Smith; Giuseppe Viale; Jo Anne Zujewski; Daniel F Hayes
Journal:  J Natl Cancer Inst       Date:  2011-09-29       Impact factor: 13.506

6.  Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis.

Authors:  Bhumsuk Keam; Seock-Ah Im; Kyung-Hun Lee; Sae-Won Han; Do-Youn Oh; Jee Hyun Kim; Se-Hoon Lee; Wonshik Han; Dong-Wan Kim; Tae-You Kim; In Ae Park; Dong-Young Noh; Dae Seog Heo; Yung-Jue Bang
Journal:  Breast Cancer Res       Date:  2011-03-02       Impact factor: 6.466

7.  Correction: Androgen Receptor (AR), E-Cadherin, and Ki-67 as Emerging Targets and Novel Prognostic Markers in Triple-Negative Breast Cancer (TNBC) Patients.

Authors:  Giuseppina Rosaria Rita Ricciardi; Barbara Adamo; Antonio Ieni; Luana Licata; Roberta Cardia; Giuseppa Ferraro; Tindara Franchina; Giovanni Tuccari; Vincenzo Adamo
Journal:  PLoS One       Date:  2015-07-02       Impact factor: 3.240

8.  P53 and Ki-67 as prognostic markers in triple-negative breast cancer patients.

Authors:  Yunbao Pan; Yufen Yuan; Guoshi Liu; Yongchang Wei
Journal:  PLoS One       Date:  2017-02-24       Impact factor: 3.240

9.  Breast cancer in a tertiary cancer center in India - An audit, with outcome analysis.

Authors:  Nita Nair; Tanuja Shet; Vani Parmar; Rohini Havaldar; Sudeep Gupta; Ashwini Budrukkar; Rajiv Sarin; Meenakshi Thakur; Sangeeta Desai; Prabha Yadav; Rakesh Jalali; Seema Gulia; Tabassum Wadasadawala; Jaya Gosh; Jyoti Bajpai; Seema Kembhavi; Asawari Patil; Shalaka Joshi; Palak Popat; Venkatesh Rangarajan; Sneha Shah; Vaibhav Vanmali; Shabina Siddiqui; Indraneel Mittra; Rajendra Badwe
Journal:  Indian J Cancer       Date:  2018 Jan-Mar       Impact factor: 1.224

  9 in total
  2 in total

1.  The role of E-Cadherin expression in primary site of breast cancer.

Authors:  Nora Karsten; Thomas Kolben; Sven Mahner; Susanne Beyer; Sarah Meister; Christina Kuhn; Elisa Schmoeckel; Rachel Wuerstlein; Nadia Harbeck; Nina Ditsch; Udo Jeschke; Klaus Friese; Theresa Maria Kolben
Journal:  Arch Gynecol Obstet       Date:  2021-09-12       Impact factor: 2.344

2.  Association of Ki-67 With Clinicopathological Factors in Breast Cancer.

Authors:  Jitendra S Nigam; Tarun Kumar; Shreekant Bharti; Ruchi Sinha; Punam P Bhadani
Journal:  Cureus       Date:  2021-06-13
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.